Codagenix Inc.
Farmingdale, NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3 Bioscience Park Dr, Farmingdale, NY 11735, USA
- Website
- codagenix.com
- Founded
- 2011
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $10,000,000 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Codagenix Inc. is a clinical stage biotechnology company that utilizes proprietary Synthetic Attenuated Virus Engineering (SAVE) technology to construct live attenuated viral vaccines across multiple targets. Their platform redesigns the entire viral genome to weaken the virus while retaining its ability to induce a robust immune response.
Codagenix Inc. has been awarded federal contracts to advance the development of COVID-19 and dengue vaccine candidates utilizing their SAVE platform. In September 2023, the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $389.4 million cost-plus-fixed-fee contract for a Phase 2B efficacy study of Codagenix's live attenuated COVID-19 vaccine, Coviliv. Codagenix will also manufacture SARS-CoV-2 antigen panel assay kits under this contract. This contract had no set-aside designation.
Through several federal grants, Codagenix has received funding to further the preclinical and clinical development of live attenuated dengue and COVID-19 vaccine candidates. In September 2023, the Defense Health Agency awarded a $5.88 million cooperative agreement for good manufacturing practice production and initial clinical evaluation of a tetravalent dengue vaccine leveraging the SAVE platform. A prior $4.44 million cooperative agreement from August 2022 supported preclinical work on the same tetravalent dengue vaccine. Additionally, a $0 project grant was awarded by the National Institute of Allergy and Infectious Diseases in May 2021 to complete final preclinical testing and formulation development for Codagenix's live attenuated COVID-19 vaccine candidate, CDX-005.
SBA capabilities narrative
Development of new and improved vaccines against infectious diseases. Vaccines against emerging or pandemic pathogens.
Quick answers
Is Codagenix Inc. registered in SAM.gov?
Yes. Codagenix Inc.'s SAM.gov registration is active through July 14, 2027.
What is Codagenix Inc.'s CAGE code?
Codagenix Inc.'s CAGE code is 5D8K5, and its Unique Entity ID (UEI) is TEMNL437K2F1.
How much has Codagenix Inc. received in federal contracts?
Federal contracts obligated $10,000,000 to Codagenix Inc. in fiscal years 2023 through 2027.
What is Codagenix Inc.'s most recent federal award?
Codagenix Inc.'s most recent federal contract award is Conduct a phase 2B efficacy study as prescribed in AOI15 with coviliv a proprietary live attenuated virus covid-19… (75A50123C00048), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2023.
On GovTribe
See Codagenix Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors